tecvayli
janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastiset aineet - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
banjo forte
adama - dimetomorf 200 g/l + fluazinam 200 g/l - kasvitautien torjunta
cloud
adama - kvinmerakki / kvinmerak 125 g/l + metatsaklori / metazaklor 375 g/l - rikkakasvien torjunta
mixin
adama - florasulaami 2,5 g/l + fluroksipyyri-i-metyyliheptyyliesteri 144 g/l - rikkakasvien torjunta